Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PLC Systems -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1156)	11/22/1999 10:20:00 AM
From: Rob C.	Read Replies (1) \| Respond to of 1202

biz.yahoo.com Monday November 22, 9:17 am Eastern Time Company Press Release SOURCE: PLC Systems Inc. TMR Presentations at the American Heart Association Meeting Reinforce PLC Systems' Position in the Marketplace FRANKLIN, Mass., Nov. 22 /PRNewswire/ -- PLC Systems Inc. (Amex: PLC - news) announced that there were 10 oral presentations and abstracts that discussed transmyocardial revascularization (TMR) with PLC's carbon dioxide (CO2) The Heart Laser(TM) System at the 72nd Scientific Sessions of the American Heart Association (AHA) held at the Georgia World Congress Center in Atlanta, GA on November 7-10, 1999. Highlights from the TMR presentations at AHA included: Dr. Robert March, assistant professor of surgery and director of cardiovascular research at Rush Medical College, Chicago, Illinois, discussed TMR with PLC's CO2 The Heart Laser System in combination with Coronary Artery Bypass Grafting (CABG). The interim results suggest that, compared to CABG alone, TMR plus CABG may improve perioperative survival and long-term therapeutic success in high-risk patients. Dr. Keith Horvath, assistant professor of surgery at Northwestern University Medical School, Chicago, Illinois presented results from a multi- center trial. The researchers concluded that patients with severe angina have significantly improved outcomes following TMR with The Heart Laser System. Study results demonstrated that TMR with PLC's carbon dioxide laser safely and effectively increases cardiac perfusion (blood flow), improves quality of life and reduces angina class. These results were recently published in the September 30, 1999 edition of The New England Journal of Medicine. Dr. John Spertus, assistant professor at The University of Missouri/Kansas City School of Medicine and director of cardiovascular education for The Mid- America Heart Institute/, Kansas City, Missouri discussed improvements in quality of life for patients undergoing TMR with The Heart Laser System. Dr. Spertus stated, ``This is the largest randomized trial of TMR reported to date. Very large improvements in symptom control, functional performance and quality of life were observed at one year among patients initially randomized to TMR. TMR holds promise as an alternative therapy for the relief of symptoms and the restoration of quality of life in patients with severe coronary artery disease.' ``The quality and quantity of the TMR presentations at the AHA is a strong reflection of the continuing adoption of TMR within the medical community,' stated Edward H. Pendergast, Chairman, President and CEO of PLC Systems. ``We are very pleased that researchers continue to demonstrate the clinical superiority of TMR with a synchronized carbon dioxide laser. PLC's The Heart Laser System is the only TMR laser that utilizes carbon dioxide as an energy source.' PLC is a leader in the development of products for performing a new surgical procedure known as transmyocardial revascularization (TMR). TMR offers a new medical treatment option for patients who suffer from severe coronary artery disease. Coronary artery disease, the leading cause of death in the United States and Europe, is expected to increase as the worldwide population continues to age. Working with leading researchers and premier heart surgery centers around the world, PLC developed the world's first FDA-approved TMR device, a high- powered laser known as The Heart Laser System. Designed to perform TMR in the safest manner possible, The Heart Laser System was approved by the U.S. Food and Drug Administration in August of 1998 for treatment of the estimated 80,000 domestic patients each year who suffer from severe coronary artery disease but cannot be treated with conventional coronary revascularization techniques such as bypass surgery or angioplasty. For more information on PLC and its products, please visit the Company's Web site at plcmed.com. Note: Certain of the above statements are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of factors, including operational changes, competitive developments, regulatory approval requirements, the ability to convince health care professionals and third party payers of the medical and economic benefits of The Heart Laser System, no assurance that all payers will reimburse health care providers who perform TMR procedures or that reimbursement, if provided, will be adequate, and risk factors described in the Company's annual report, SEC form 10-K for fiscal year ended December 31, 1998, and the Company's other SEC reports. SOURCE: PLC Systems Inc. -------------------------------------------------------------------------------- More Quotes and News: PLC Systems Inc (AMEX:PLC - news) Related News Categories: medical/pharmaceutical

To: tuck who wrote (1156)	12/28/1999 8:20:00 AM
From: Rob C.	Read Replies (1) \| Respond to of 1202

PHILADELPHIA--(BUSINESS WIRE)--Dec. 28, 1999--Acrodyne Communications, Inc. (NASDAQ: ACRO.O) and PLC Systems Inc. (AMEX: PLC.A) will be discussed by Laidlaw Insiders Trend Fund Analyst, Anthony Marchese, on RadioWallStreet on Tuesday, December 28, 1999 at 2:00 PM EST, Investor Broadcast Network, f/k/a Vcall Corporation, announced. Steven Buchsbaum, a Commentator for RadioWallStreet, will conduct the interview. To access this RadioWallStreet broadcast, investors should go to radiowallstreet.com. Listeners should go to the website at least fifteen minutes before these events to register, download, and install any necessary audio software. For those unable to attend the live broadcast, replays will be available beginning approximately one hour after each event. There is no charge to access any event. If you are viewing this release after the day of the event, you will find this interview in the "All Recent Shows" section of the website. About Investor Broadcast Network Investor Broadcast Network, founded as Vcall in 1997, is the leading webcaster of investor events covering over 1200 public companies. The Company provides compelling investor content direct from companies and experts to more than 375,000 registered users through its Vcall, RadioWallStreet and Investor Conference broadcast services. RadioWallStreet provides unique and compelling interviews and roundtable discussions from leading executives and market experts for investors who need real-time analysis and insight direct from today's newsmakers. For more information on Investor Broadcast Network visit www.investorbroadcast.com. Questions for this RadioWallStreet event may be submitted in advance by e-mailing greg@vcall.com. Please reference date and time of the interview in the Subject of the e-mail.